173 related articles for article (PubMed ID: 9416653)
21. Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment.
Peralta V; Cuesta MJ; Martinez-Larrea A; Serrano JF
Am J Psychiatry; 2000 Sep; 157(9):1461-6. PubMed ID: 10964863
[TBL] [Abstract][Full Text] [Related]
22. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
[TBL] [Abstract][Full Text] [Related]
23. Assessment of extrapyramidal symptoms during acute neuroleptic treatment.
Mazure CM; Cellar JS; Bowers MB; Nelson JC; Takeshita J; Zigun B
J Clin Psychiatry; 1995 Mar; 56(3):94-100. PubMed ID: 7883736
[TBL] [Abstract][Full Text] [Related]
24. Trajectories and antecedents of treatment response over time in early-episode psychosis.
Levine SZ; Rabinowitz J
Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients.
Tuninger E; Levander S
Acta Psychiatr Scand; 1997 Nov; 96(5):347-53. PubMed ID: 9395152
[TBL] [Abstract][Full Text] [Related]
26. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.
Leatherman SM; Liang MH; Krystal JH; Lew RA; Valley D; Thwin SS; Rosenheck RA;
J Nerv Ment Dis; 2014 Jan; 202(1):13-7. PubMed ID: 24375206
[TBL] [Abstract][Full Text] [Related]
27. Patterns of symptoms in neuroleptic-naive patients with schizophrenia and related psychotic disorders before and after treatment.
Peralta V; Cuesta MJ; Martinez-Larrea A; Serrano JF
Psychiatry Res; 2001 Dec; 105(1-2):97-105. PubMed ID: 11740979
[TBL] [Abstract][Full Text] [Related]
28. Lack of gender differences in neuroleptic response in patients with schizophrenia.
Pinals DA; Malhotra AK; Missar CD; Pickar D; Breier A
Schizophr Res; 1996 Dec; 22(3):215-22. PubMed ID: 9000318
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
Bobes J; Arango C; Garcia-Garcia M; Rejas J;
J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
[TBL] [Abstract][Full Text] [Related]
30. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
[TBL] [Abstract][Full Text] [Related]
31. Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study.
Sramek JJ; Simpson GM; Morrison RL; Heiser JF
J Clin Psychiatry; 1986 Jun; 47(6):305-9. PubMed ID: 2872206
[TBL] [Abstract][Full Text] [Related]
32. Schizoaffective disorder: a form of schizophrenia or affective disorder?
Evans JD; Heaton RK; Paulsen JS; McAdams LA; Heaton SC; Jeste DV
J Clin Psychiatry; 1999 Dec; 60(12):874-82. PubMed ID: 10665641
[TBL] [Abstract][Full Text] [Related]
33. Methylphenidate challenge as a predictor of relapse in schizophrenia.
Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B
Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506
[TBL] [Abstract][Full Text] [Related]
34. [Minor neurological and physical anomalies in patients with first-episode psychosis].
Mhalla A; Boussaïd N; Gassab L; Gaha L; Mechri A
Encephale; 2013 Jun; 39(3):149-54. PubMed ID: 23095597
[TBL] [Abstract][Full Text] [Related]
35. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
Modestin J; Wehrli MV; Stephan PL; Agarwalla P
Schizophr Res; 2008 Mar; 100(1-3):97-107. PubMed ID: 18055180
[TBL] [Abstract][Full Text] [Related]
36. Time course of antipsychotic effects of neuroleptic drugs.
Keck PE; Cohen BM; Baldessarini RJ; McElroy SL
Am J Psychiatry; 1989 Oct; 146(10):1289-92. PubMed ID: 2571305
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features.
Yung AR; Phillips LJ; Yuen HP; McGorry PD
Schizophr Res; 2004 Apr; 67(2-3):131-42. PubMed ID: 14984872
[TBL] [Abstract][Full Text] [Related]
38. The impact of neuroleptic dosage and extrapyramidal side effects on schizophrenic basic symptoms.
Moritz S; Krausz M; Gottwalz E; Andresen B
Compr Psychiatry; 2000; 41(4):284-8. PubMed ID: 10929797
[TBL] [Abstract][Full Text] [Related]
39. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
[TBL] [Abstract][Full Text] [Related]
40. Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia.
Hoff AL; Svetina C; Shields G; Stewart J; DeLisi LE
Schizophr Res; 2005 Oct; 78(1):27-34. PubMed ID: 15964177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
